地西他滨对猪圆环病毒2型的体外抑制作用

doi:10.11843/j.issn.0366-6964.2023.12.023

摘要/Abstract

摘要： 猪圆环病毒2型(PCV2)作为无囊膜单股负链环状DNA病毒,能引起感染猪的免疫抑制,是猪圆环病毒相关疾病的主要病原体,广泛传播于世界各地,给全球养猪业造成了巨大损失。为探究地西他滨(DAC)对PCV2增殖的影响及其作用机制。本研究构建了感染PCV2的PK-15细胞模型,使用CCK-8法检测DAC对PK-15细胞的细胞毒性,进而使用荧光定量PCR、间接免疫荧光和Western blot检测DAC对PCV2增殖水平的影响;通过间接免疫荧光法标记5甲基胞嘧啶表征DAC对细胞基因组DNA全局甲基化的影响;通过RNA干扰技术在PK-15细胞中沉默DAC的作用靶点DNA甲基转移酶1(Dnmt1),进一步探究DAC抑制PCV2增殖的作用机理。结果显示,DAC在20 μmol·L^-1时才具有轻微的细胞毒性,并在浓度为10 μmol·L^-1时即表现出明显的抗PCV2活性,可以抑制不同时间的PCV2增殖。DAC处理细胞后能显著降低PK-15细胞基因组DNA的甲基化,并诱导Ⅰ型干扰素(Ⅰ-IFN)和干扰素刺激基因(ISGs)的表达。沉默DAC的作用靶点Dnmt1能显著抑制PCV2的增殖,且同样诱导I-IFN和ISGs的表达。本研究证实DAC能够有效抑制PCV2的增殖,且发现DAC能促进I-IFN和ISGs的表达并抑制DNA的甲基化,推测DAC抗PCV2病毒的功能与I-IFN和ISGs的表达上调有关,提示DAC具备开发成PCV2临床抗病毒药物的潜力,还揭示Dnmt1是激活宿主固有免疫抗病毒通路的潜在靶点,为新的PCV2抗病毒药物研发提供理论依据。

关键词: 地西他滨, 猪圆环病毒, 抗病毒, 固有免疫

Abstract: Porcine circovirus type 2 (PCV2) is a non-enveloped single-stranded negative-strand circular DNA virus that can cause immunosuppression in infected pigs. It is the main pathogen of porcine circovirus associated diseases and is widely spread around the world. The purpose of this paper is to explore the effect of decitabine (DAC) on the proliferation of PCV2 and its mechanism. In this study, a PK-15 cell model infected with PCV2 was constructed, and the cytotoxicity of DAC to PK-15 cells was detected by CCK-8 method, and then the effect of DAC on the proliferation of PCV2 was detected by fluorescent quantitative PCR, indirect immunofluorescence and Western blot. The effect of DAC on the global methylation of cellular genomic DNA was characterized by labeling 5-methylcytosine by indirect immunofluorescence method; Dnmt1(DNA methytransferase 1), as the target of DAC in PK-15 cells, was silenced by RNA interference technology, to further explore the inhibitory effect of DAC on PCV2 proliferation. The results showed that DAC had slight cytotoxicity at 20 μmol·L^-1, and showed obvious anti-PCV2 activity at a concentration of 10 μmol·L^-1, and could inhibit the proliferation of PCV2 at different times. DAC treatment of cells can significantly reduce the methylation level of genomic DNA in PK-15 cells and induce the expression of type Ⅰ interferon (Ⅰ-IFN) and interferon-stimulated genes (ISGs). Silencing Dnmt1, the target of DAC, significantly inhibited the proliferation of PCV2 and induced the expression of I-IFN and ISGs. This study confirmed that DAC can play an anti-PCV2 function by inhibiting DNA methylation and promoting the expression of I-IFN and ISGs. Furthermore, DAC has the potential to be developed into a clinical antiviral drug against PCV2, Dnmt1 is a potential target for activating the host's innate immune antiviral pathway, providing a theoretical basis for the development of new PCV2 antiviral drugs.

Key words: decitabine, PCV2, antiviral, innate immunity

中图分类号:

范锦全, 张宇航, 唐午阳, 赵欣宇, 李丕顺, 郑晓峰. 地西他滨对猪圆环病毒2型的体外抑制作用[J]. 畜牧兽医学报, 2023, 54(12): 5134-5142.

FAN Jinquan, ZHANG Yuhang, TANG Wuyang, ZHAO Xinyu, LI Pishun, ZHENG Xiaofeng. Inhibitory Effect of Decitabine on Porcine Circovirus Type 2 in vitro[J]. Acta Veterinaria et Zootechnica Sinica, 2023, 54(12): 5134-5142.

参考文献

[1] MEEHAN B M, MCNEILLY F, TODD D, et al. Characterization of novel circovirus DNAs associated with wasting syndromes in pigs[J]. J Gen Virol, 1998, 79(9):2171-2179.
[2] MENG X J. Porcine circovirus type 2(PCV2):pathogenesis and interaction with the immune system[J]. Annu Rev Anim Biosci, 2013, 1:43-64.
[3] SUN J H, HUANG L P, WEI Y W, et al. Prevalence of emerging porcine parvoviruses and their co-infections with porcine circovirus type 2 in China[J]. Arch Virol, 2015, 160(5):1339-1344.
[4] MENG X J. Spread like a wildfire—the omnipresence of porcine circovirus type 2(PCV2) and its ever-expanding association with diseases in pigs[J]. Virus Res, 2012, 164(1-2):1-3.
[5] PARVATHANENI V, KULKARNI N S, MUTH A, et al. Drug repurposing:a promising tool to accelerate the drug discovery process[J]. Drug Discov Today, 2019, 24(10):2076-2085.
[6] DHILLON S. Decitabine/cedazuridine:first approval[J]. Drugs, 2020, 80(13):1373-1378.
[7] KAMINSKAS E, FARRELL A, ABRAHAM S, et al. Approval summary:azacitidine for treatment of myelodysplastic syndrome subtypes[J]. Clin Cancer Res, 2005, 11(10):3604-3608.
[8] XIAO J, LIU P, WANG Y L, et al. A novel cognition of decitabine:insights into immunomodulation and antiviral effects[J]. Molecules, 2022, 27(6):1973.
[9] BOUCHARD J, WALKER M C, LECLERC J M, et al. 5-azacytidine and 5-azadeoxycytidine inhibit human immunodeficiency virus type 1 replication in vitro[J]. Antimicrob Agents Chemother, 1990, 34(2):206-209.
[10] WANG Y Y, HAO J L, LIU X H, et al. The mechanism of apoliprotein A1 down-regulated by hepatitis B virus[J]. Lipids Health Dis, 2016, 15:64.
[11] MOREL A, BAGUET A, PERRARD J, et al. 5azadC treatment upregulates miR-375 level and represses HPV16 E6 expression[J]. Oncotarget, 2017, 8(28):46163-46176.
[12] THIEULENT C, HUE E S, SUTTON G, et al. Identification of antiviral compounds against equid herpesvirus-1 using real-time cell assay screening:efficacy of decitabine and valganciclovir alone or in combination[J]. Antiviral Res, 2020, 183:104931.
[13] KWAK J, SHIM J H, TIWARI I, et al. Hepatitis C virus core protein inhibits E6AP expression via DNA methylation to escape from ubiquitin-dependent proteasomal degradation[J]. Cancer Lett, 2016, 380(1):59-68.
[14] SPEARMAN C. The method of 'right and wrong cases’ ('constant stimuli’) without gauss's formulae[J]. Br J Psychol, 1908, 2(3):227-242.
[15] KÄRBER G. Beitrag zur kollektiven behandlung pharmakologischer reihenversuche[J]. Naunyn Schmiedebergs Arch Exp Pathol Pharmakol, 1931, 162(4):480-483.
[16] AFGHAH Z, WEBB B, MENG X J, et al. Ten years of PCV2 vaccines and vaccination:Is eradication a possibility?[J]. Vet Microbiol, 2017, 206:21-28.
[17] XU T, ZHANG Y H, TIAN R B, et al. Prevalence and genetic analysis of porcine circovirus type 2(PCV2) and type 3(PCV3) between 2018 and 2020 in central China[J]. Infect Genet Evol, 2021, 94:105016.
[18] YU J, QIN B, MOYER A M, et al. DNA methyltransferase expression in triple-negative breast cancer predicts sensitivity to decitabine[J]. J Clin Invest, 2018, 128(6):2376-2388.
[19] DINARDO C D, PRATZ K, PULLARKAT V, et al. Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia[J]. Blood, 2019, 133(1):7-17.
[20] CHIAPPINELLI K B, STRISSEL P L, DESRICHARD A, et al. Inhibiting DNA methylation causes an interferon response in cancer via dsRNA including endogenous retroviruses[J]. Cell, 2015, 162(5):974-986.
[21] ROULOIS D, LOO YAU H, SINGHANIA R, et al. DNA-demethylating agents target colorectal cancer cells by inducing viral mimicry by endogenous transcripts[J]. Cell, 2015, 162(5):961-973.
[22] MORALES-NEBREDA L, MCLAFFERTY F S, SINGER B D. DNA methylation as a transcriptional regulator of the immune system[J]. Transl Res, 2019, 204:1-18.
[23] DE CUBAS A A, DUNKER W, ZANINOVICH A, et al. DNA hypomethylation promotes transposable element expression and activation of immune signaling in renal cell cancer[J]. JCI Insight, 2020, 5(11):e137569.